Osman Kibar

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

T. Rowe Price Associates, Inc. (Price Associates) is a registered investment advisor and mutual fund manager headquartered in Baltimore, Maryland. The firm was founded by Thomas Rowe Price, Jr. in 1937. They are a subsidiary of the T. Rowe Price Group, Inc. (NASDAQ: TROW), which was formed in 2000 as the publicly traded parent holding company of Price Associates and their affiliated entities. Price Associates offers a variety of mutual funds, sub-advisory services and separate account management for individual and institutional investors, retirement plans and financial intermediaries.

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Eventide Asset Management LLC (Eventide) is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. The firm was founded in 2008 by Finni Kuruvilla, Jason Myhre, Roben John, David Barksdale and Anil Thomas. Eventide provides portfolio management for registered mutual funds and offers non-discretionary Model Allocations and Models to financial intermediaries such as wrap fee program sponsors.

Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina.

ST Engineering Electronics Ltd. manufactures electronics and information communications technology solutions. The company was founded in 1969 and is headquartered in Singapore.

Greywolf Capital Management LP (Greywolf Capital) is an independent, SEC-registered investment advisor and hedge fund firm headquartered in Purchase, New York. The firm was founded in 2003 by Bob Miller, Jonathan Savitz, William Troy and James Gillespie. Greywolf Capital provides investment advisory services to (i) private investment funds that are primarily offered to institutional investors and financially sophisticated high net worth individuals and (ii) separately managed accounts, primarily for the foregoing types of investors.

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Vickers Venture Partners (S) Pte Ltd. (Vickers Venture Partners) is a venture capital firm founded in 2005 by Dr. Finian Tan Seng Chin, Drs. Khalil Binebine, Jeffrey Chi, Damian Tan, and Ms. Linda Li. The firm is headquartered in Singapore with offices in New York, Silicon Valley, London and Shanghai.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

MatchMove Pay Pte Ltd. engages in the provision of end-to-end enterprise mobile wallet and payment card solutions. Its secure mobile wallet solutions include P2P transfer, cross-border money transfers, top up channels, virtual payment cards, loyalty points and rewards, promotions and offers. The company was founded by Shailesh Naik and Hsueh Huah Leow and is headquartered in Singapore.

KPISOFT Pte Ltd. operates as an investment holding company. The company was founded by Ravee Ramamoothie and Naveen Deshpande and is headquartered in Singapore.

Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA.

Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA.

Part of UCB SA, UCB Biopharma SRL is a Belgian pharmaceutical company founded in 2013. The company is based in Brussels, Belgium. UCB Biopharma specializes in the development of treatments for various medical conditions, including axial spondyloarthritis, psoriatic arthritis, and other health issues. The company also manages the UCB Community Health Fund and holds an annual shareholders meeting.

Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA.

LetsGetChecked, Inc. operates online platform which connects customers and diagnostic laboratories. It offers its diagnostics services for general health, sexual health, cancer screening and fertility and hormone check. The company was founded by Peter Foley in 2014 and is headquartered in Dun Laoghaire, Ireland.

MyGini, Inc. engages in the development and design of plug and play payments and loyalty platform. Its product under myGini application provides loyalty and offers management; spending controls and budgeting tools; card management; and mobile payment functionality. The company was founded by Mehmet Sezgin in 2016 and is headquartered in San Francisco, CA.

Emergex Vaccines Holding Ltd. is a biotechnology company, which engages in the development of medicines against viral and bacterial infectious diseases. It focuses on the vaccines for dengue fever, Zika, Ebola, pandemic flu, and serious intra-cellular bacterial infections. The company was founded by Storme Moore-Thornicroft and Thomas Rademacher in 2016 and is headquartered in Abingdon, the United Kingdom.

Eavor Technologies, Inc. generates green baseload power. The company was founded in 2017 and is headquartered in Calgary, Canada.

Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.

Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA.

Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY.

Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation.